Fatima Cardoso, MD
European School of Oncology Breast Cancer Program Coordinator
Secretary General, European Organization for Research and Treatment of Cancer
Director, Breast Cancer Unit
Champalimaud Cancer Center
2013-2014 BCRF Project:
(The Play for P.I.N.K. Award)
On behalf of Breast International Group (BIG) and The North American Breast Cancer Groups (NABCG)
Co-Investigators: John M.S. Bartlett, MD, The University of Edinburgh, Edinburgh, Scotland; Peggy L. Porter, MD, Fred Hutchinson Cancer Research Center, Seattle, WA; and Sharon Giordano, MD, MPH, University of Texas MD Anderson Cancer Center
Due to the rarity of the male breast cancer, international cooperation is necessary to undertake relevant projects with potential clinical impact. With BCRF support, the Male Breast Cancer International Registration and Biologic Characterization Program has been launched, as a joint effort between the Breast International Group (BIG) and the North American Breast Cancer Groups (NABCG) and coordinated by the European Organization for the Research and Treatment of Cancer (EORTC). In the first part of this program, clinical data and tumor samples from male BC cases treated in the last 20 years are being collected. Patients are accruing rapidly, with about 1600 patients registered, which makes this study the largest series of male breast cancer cases ever investigated. The pathology analysis of these tumor samples in the central labs has begun and will lead to a better understanding of the biological characteristics of this disease and to the identification of important potential prognostic (indicative of the good or bad outcome of the disease) and predictive (indicative of probability of response to certain therapies) markers. In 2013-2014, this international team plans to launch the second part of this program, a prospective registry, and will continue negotiations for the third part, a prospective clinical trial.
The accrual closed early September 2013 and 1,800 patients have been registered. This is the largest series of male breast cancer ever studied. The pathology analysis of these tumor samples in the central labs is ongoing and will lead to a better understanding of the biological characteristics of this disease and to the identification of important potential prognostic (indicative of the good or bad outcome of the disease) and predictive (indicative of probability of response to certain therapies) markers. A 1st presentation of these data is expected during the 9th European Breast Cancer Conference, in Glasgow, Scotland, in March 2014. The second part of this program, a prospective registry, has just been launched (first patients are expected in February 2014) and negotiations are ongoing for the third part, a prospective clinical trial.
Dr. Cardoso is the Director of the Breast Cancer Unit of the Champalimaud Cancer Center in Lisbon, Portugal. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium (Prof. Martine Piccart), and Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas (Prof. Mien-Chie Hung). She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational
Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine.
Dr. Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for seven years.
Dr. Cardoso is actively involved in numerous professional organizations including the European Society of Medical Oncology, European Organization for Research and Treatment of Cancer (EORTC), American Society of Clinical Oncology, and American Association for Cancer Research where she serves on several committees, and is the current EORTC Secretary General and vice-chair of the EORTC-Breast Cancer Group.
She is the Breast Cancer Program Coordinator of the European School of Oncology and co-chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC). Dr. Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals.
In addition to support from BCRF, she has received educational and research grants from the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), the Portuguese Science and Technology Foundation (FCT), the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the "Fonds Jean-Claude Heuson," the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme.
Dr. Cardoso has authored over 200 publications and has presented her work nationally and internationally.